CYTKHIGH SIGNALFINANCIAL10-K

Cytokinetics experienced a dramatic revenue collapse while significantly increasing debt financing and R&D spending, indicating a major business transition.

The company appears to have transitioned from a revenue-generating phase back to a pre-commercial development stage, with revenue falling to just $13.4M from over $100M in the prior year. The simultaneous 35.6% increase in total liabilities to $2.1B and 22.6% rise in R&D expenses suggests the company is funding intensive drug development through debt financing, creating significant financial risk if clinical programs fail to deliver.

Comparing 2026-02-26 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company in major transition, with revenue declining substantially while R&D expenses grew meaningfully to $416M, indicating heavy investment in drug development. Despite the revenue collapse, cash position improved modestly to $122.5M, though this was offset by a significant increase in total liabilities to $2.1B. Operating cash outflow worsened to -$510M, reflecting the substantial cash burn rate typical of a biotech company in intensive development mode rather than commercial operations.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-87.4%
$106.4M→$13.4M

Revenue declined 87.4% — significant demand weakness or market share loss warrants investigation.

Total Liabilities
Balance Sheet
+35.6%
$1.5B→$2.1B

Liabilities grew 35.6% — significant increase in debt or obligations, assess impact on financial flexibility.

Net Income
P&L
-33.2%
-$589.5M→-$785.0M

Net income declined 33.2% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+29.2%
$94.9M→$122.5M

Cash grew 29.2% — improving liquidity position supports investment and shareholder returns.

Operating Cash Flow
Cash Flow
-28.8%
-$395.9M→-$510.0M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

R&D Expense
P&L
+22.6%
$339.4M→$416.0M

R&D investment increased 22.6% — signals commitment to future product development, though near-term margin impact.

Interest Expense
P&L
+20.9%
$37.7M→$45.6M

Interest costs rose 20.9% — monitor debt levels and coverage ratio in rising rate environment.

Current Assets
Balance Sheet
-17.2%
$1.1B→$917.0M

Current assets declined 17.2% — monitor working capital adequacy and short-term liquidity.

Operating Income
P&L
-14.2%
-$536.2M→-$612.3M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Current Liabilities
Balance Sheet
+12.7%
$179.7M→$202.5M

Current liabilities rose 12.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-27
ADDED
(A) (A) Excludes 43.8 million shares of common stock held by directors and executive officers, and any stockholders known to us whose ownership exceeded ten percent of our common stock outstanding as of June 30, 2025.
Bank National Association), as trustee, as supplemented by the First Supplemental Indenture, dated November 13, 2019, between Cytokinetics and U.S.
Bank National Association) 2026 Notes Cytokinetics 4% convertible senior notes due 2026 2027 Indenture Indenture, dated July 6, 2022, between Cytokinetics and U.S.
Bank Trust Company, as trustee 2027 Notes Cytokinetics 3.50% convertible senior notes due 2027 2031 Indenture Indenture, dated September 19, 2025, between Cytokinetics and U.S.
Food and Drug Administration Final Payment Amount As defined in Part II, Item 7 (Management s Discussion and Analysis of Financial Conditions and Results of Operations) of this Annual Report on Form 10-K Sources and Uses of Cash, Royalty Pharma Transactions FOREST-HCM Five-Year, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM Fundamental Change As defined in the 2026 Indenture, 2027 Indenture, or 2031 Indenture, as applicable GAAP Generally Accepted Accounting Principles in the U.S.
+7 more — sign up free →
REMOVED
(A) (A) Excludes 13.7 million shares of common stock held by directors and executive officers, and any stockholders whose ownership exceeds ten percent of the shares outstanding, at June 28, 2024.
Food and Drug Administration Final Payment Amount As defined in Part II, Item 7 (Management s Discussion and Analysis of Financial Conditions and Results of Operations) of this Annual Report on Form 10-K Sources and Uses of Cash, Royalty Pharma Transactions FOREST-HCM Five-Year, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM FSTA fast skeletal muscle troponin activator Fundamental Change As defined in the 2027 Indenture GAAP Generally Accepted Accounting Principles in the U.S.
1, dated January 7, 2022 RP Stock Purchase Agreement Common Stock Option and Purchase Agreement, dated May 22, 2024, by and between Cytokinetics and Royalty Pharma Investments 2019 ICAV RPDF Royalty Pharma Development Funding, LLC RPFT RPI Finance Trust RPI ICAV Royalty Pharma Investments 2019 ICAV RSU Restricted Stock Unit RTW ICAV RTW Investments ICAV for RTW Fund 1 RTW Investors RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd.
We intend that such statements be protected by the safe harbor created thereby.
Forward-looking statements involve risks and uncertainties and our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →